MYPN Gene

MYPN Gene

Overview

MYPN (Myopalladin) encodes a critical Z-disc protein that plays essential roles in sarcomere organization, assembly, and maintenance in both skeletal and cardiac muscle. Located at chromosome 10q21.3, myopalladin serves as a molecular scaffold that integrates multiple protein complexes at the Z-disc, connecting the contractile apparatus to the structural framework of the muscle fiber. The protein was first characterized in the early 2000s and has since been recognized as an important regulator of muscle structure and function.

The discovery of disease-causing mutations in MYPN established this gene as a significant cause of inherited cardiomyopathies and skeletal myopathies. Patients with MYPT-related disease present with a spectrum of phenotypes ranging from isolated cardiomyopathy to combined cardiac and skeletal muscle involvement. The identification of MYPN as a disease gene has provided important insights into Z-disc biology and the pathogenesis of related muscle disorders.

MYPN Gene

Overview

MYPN (Myopalladin) encodes a critical Z-disc protein that plays essential roles in sarcomere organization, assembly, and maintenance in both skeletal and cardiac muscle. Located at chromosome 10q21.3, myopalladin serves as a molecular scaffold that integrates multiple protein complexes at the Z-disc, connecting the contractile apparatus to the structural framework of the muscle fiber. The protein was first characterized in the early 2000s and has since been recognized as an important regulator of muscle structure and function.

The discovery of disease-causing mutations in MYPN established this gene as a significant cause of inherited cardiomyopathies and skeletal myopathies. Patients with MYPT-related disease present with a spectrum of phenotypes ranging from isolated cardiomyopathy to combined cardiac and skeletal muscle involvement. The identification of MYPN as a disease gene has provided important insights into Z-disc biology and the pathogenesis of related muscle disorders.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.2em;">MYPN</th></tr>
<tr><td colspan="2" style="text-align:center;font-style:italic;">Myopalladin</td></tr>
<tr><th style="width:40%;">Gene Symbol</th><td><strong>MYPN</strong></td></tr>
<tr><th>Full Name</th><td>Myopalladin</td></tr>
<tr><th>Chromosome</th><td>10q21.3</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/84665" target="_blank">84665</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138379" target="_blank">ENSG00000138379</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/608002" target="_blank">608002</a></td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q8WWI5" target="_blank">Q8WWI5</a></td></tr>
<tr><th>Protein Length</th><td>1,456 amino acids</td></tr>
<tr><th>Molecular Weight</th><td>162 kDa</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Gene Structure and Expression

Genomic Organization

The MYPN gene spans approximately 27 kilobases on chromosome 10q21.3 and consists of 30 exons that encode a 1,456-amino acid protein. The gene has a relatively simple structure compared to other sarcomeric protein genes, with the coding sequence contained within a single large exon in some transcripts. This genomic organization is notable because many disease-causing mutations cluster in specific functional domains rather than being distributed evenly across the gene.

The MYPN promoter contains regulatory elements that direct muscle-specific expression. The transcriptional control involves multiple muscle-specific transcription factors including MyoD, myogenin, and serum response factor (SRF). These factors bind to consensus sequences within the MYPN promoter to activate transcription in skeletal and cardiac muscle cells.

Tissue Distribution

MYPN exhibits a muscle-specific expression pattern with some notable differences between isoforms:

• Skeletal Muscle: High expression in all major skeletal muscle groups, with particularly abundant levels in type 1 (slow-twitch) fibers.
• Cardiac Muscle: Very high expression in both ventricular and atrial myocardium, reflecting the protein's critical role in cardiac function.
• Smooth Muscle: Low to undetectable expression in most smooth muscle populations.
• Non-muscle Tissues: Minimal expression outside of muscle tissues, confirming its role as a muscle-specific protein.

Protein Structure and Function

Domain Architecture

Myopalladin is a large protein with multiple functional domains that mediate its interactions with other sarcomeric proteins:

Normal Cellular Functions

Myopalladin performs several essential functions in muscle cells:

Z-Disc Organization

As a Z-disc protein, myopalladin plays a central role in organizing this critical structural element. The Z-disc serves as the boundary between adjacent sarcomeres and anchors the thin (actin) filaments. Myopalladin interacts with multiple Z-disc components to maintain proper organization:

• Alpha-actinin binding: Myopalladin directly binds to alpha-actinin, the primary cross-linking protein at the Z-disc. This interaction is essential for forming the lattice-like structure of the Z-disc.
• Nebulin interaction: The central region of myopalladin interacts with nebulin, a giant protein that runs along thin filaments and regulates their length and organization. This interaction coordinates Z-disc structure with thin filament organization.
• Titin connection: Myopalladin interacts with titin, the giant protein that spans half the sarcomere, linking the Z-disc to the thick filament system.

Sarcomere Assembly

During muscle development and regeneration, myopalladin is recruited early to forming Z-discs where it nucleates the assembly of other Z-disc proteins. Studies have demonstrated that myopalladin is one of the first proteins to accumulate at nascent Z-discs during sarcomere formation [@nakano2016]. This early recruitment suggests that myopalladin may serve as a master organizer that coordinates the assembly of the entire Z-disc structure.

Nuclear Signaling

A unique feature of myopalladin is its ability to localize to the nucleus, where it interacts with CARP (cardiac ankyrin repeat protein). This nuclear function links sarcomere structure to gene expression regulation:

• Transcriptional Regulation: The myopalladin-CARP complex regulates the expression of genes involved in muscle differentiation and maintenance.
• Signal Integration: Nuclear myopalladin may integrate mechanical and developmental signals to coordinate muscle gene expression.
• Pathogenic Implications: Disruption of the nuclear localization or CARP interaction may contribute to disease pathogenesis.

Mechanical Coupling

By connecting multiple proteins at the Z-disc, myopalladin contributes to the mechanical coupling between adjacent sarcomeres and to the lateral force transmission within muscle fibers. This function is essential for efficient force generation and for maintaining structural integrity during contraction.

Disease Associations

Cardiomyopathy

MYPN mutations are a well-established cause of inherited cardiomyopathies, particularly dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) [@wang2010]:

Dilated Cardiomyopathy (DCM)

• Prevalence: MYPN mutations account for approximately 1-2% of familial DCM cases.
• Penetrance: Variable, with many mutation carriers developing disease in adulthood.
• Phenotype: Characterized by dilation of the left ventricle, systolic dysfunction, and progressive heart failure.
• Arrhythmias: Patients are at increased risk of ventricular arrhythmias and may require device therapy (ICD) for primary prevention.

Hypertrophic Cardiomyopathy (HCM)

• Prevalence: MYPN mutations are less common in HCM than in DCM, accounting for less than 1% of cases.
• Phenotype: Concentric or asymmetric hypertrophy of the ventricles, particularly the interventricular septum.
• Outflow Obstruction: Dynamic obstruction to left ventricular outflow may be present in some patients.

Restrictive Cardiomyopathy (RCM)

• Rare cases of MYPN-related restrictive cardiomyopathy have been reported, characterized by impaired ventricular filling with normal or reduced ventricular volumes.

Nemaline Myopathy

MYPN mutations are a recognized cause of nemaline myopathy, a congenital myopathy characterized by the presence of nemaline rods (thin, rod-like structures) within muscle fibers [@miyazaki2012]:

Clinical Features

• Onset: Typically presents in infancy or early childhood, although adult-onset cases are recognized.
• Muscle Weakness: Predominantly affects axial and proximal muscles, with facial and bulbar involvement common.
• Respiratory Involvement: Many patients develop respiratory insufficiency requiring ventilatory support.
• Contractures: Joint contractures may develop, particularly in severe cases.
• Cardiac Involvement: Some patients have concurrent cardiomyopathy, creating a combined phenotype.

Pathological Features

• Nemaline Rods: Small, rod-shaped inclusions that represent abnormal accumulations of Z-disc proteins.
• Fiber Type Variation: Type 1 fiber predominance and atrophy are common findings.
• Myopalladin Accumulation: Immunohistochemistry shows abnormal myopalladin accumulation within muscle fibers.

Myofibrillar Myopathy

MYPN mutations can also cause a myofibrillar myopathy phenotype characterized by:

• Protein Aggregates: Abnormal protein accumulations containing myopalladin and other Z-disc proteins.
• Sarcomere Disruption: Focal dissolution of sarcomere structure with accumulation of degraded proteins.
• Progressive Weakness: Slowly progressive muscle weakness with onset in adulthood.

Pediatric Cardiomyopathy

MYPN mutations are increasingly recognized as a cause of pediatric-onset cardiomyopathy, sometimes presenting in infancy [@filomena2020]:

• Severe Phenotypes: Some mutations cause early-onset, severe cardiomyopathy requiring heart transplantation.
• Extracardiac Manifestations: Some patients have additional skeletal muscle involvement.
• Developmental Delay: Rare cases are associated with neurodevelopmental abnormalities.

Molecular Mechanisms

Pathogenic Mechanisms

The mechanisms by which MYPN mutations cause disease include several interconnected processes:

Loss of Function

Most disease-causing mutations result in reduced or absent myopalladin function:

• Truncated Proteins: Nonsense and frameshift mutations produce truncated proteins that cannot perform normal functions.
• Misfolded Proteins: Missense mutations may cause improper folding, leading to degradation or mislocalization.
• Reduced Expression: Some mutations affect RNA splicing or stability, reducing protein levels.

Toxic Gain of Function

Certain mutations may confer abnormal properties:

• Aggregation-Prone Mutants: Some disease-causing variants form intracellular aggregates that disrupt cellular function.
• Dominant-Negative Effects: Mutant proteins may interfere with normal protein function through inappropriate interactions.
• Impaired Degradation: Mutations may overload the cellular protein quality control systems.

Nuclear Dysfunction

Disruption of the nuclear functions of myopalladin:

• CARP Mislocalization: Mutations affecting the CARP-binding domain may disrupt nuclear signaling.
• Transcriptional Dysregulation: Altered nuclear myopalladin may affect gene expression patterns.
• Developmental Abnormalities: Impaired nuclear signaling during development may contribute to congenital myopathy.

Signaling Pathways

Myopalladin participates in several important signaling pathways:

Mechanical Signaling

The protein serves as a mechanosensor that responds to mechanical stress:

• Force Transmission: By connecting multiple Z-disc proteins, myopalladin participates in transmitting contractile force.
• Stretch Response: Mechanical stretch activates signaling pathways that involve myopalladin.
• Pathological Remodeling: Abnormal mechanical signaling in mutant myopalladin may contribute to disease progression.

Protein Quality Control

Myopalladin turnover involves multiple cellular pathways:

• Ubiquitin-Proteasome System: Most myopalladin degradation occurs through the proteasome.
• Autophagy-Lysosome Pathway: Aggregate-prone mutants may be cleared through autophagy.
• Chaperone Involvement: Molecular chaperones regulate myopalladin folding and stability.

Animal Models

Knockout Mice

Mice lacking myopalladin develop cardiomyopathy with features similar to human disease [@chandra2022]:

• Cardiac Phenotype: Progressive dilation and systolic dysfunction.
• Skeletal Muscle: Subtle structural abnormalities without significant weakness.
• Mechanism: Loss of Z-disc organization and disrupted mechanotransduction.

Transgenic Models

Transgenic mice expressing mutant MYPN develop cardiomyopathy:

• Dominant-Negative Effects: Mutant proteins disrupt normal myopalladin function.
• Aggregation: Mutant proteins form intracellular aggregates.
• Therapeutic Testing: These models have been used to test potential therapeutic interventions.

Clinical Diagnosis

Genetic Testing

Molecular diagnosis of MYPN-related disease involves:

Clinical Evaluation

Patients with MYPN-related disease require comprehensive assessment:

• Cardiac Evaluation: ECG, echocardiography, and cardiac MRI to characterize cardiac involvement.
• Neurological Evaluation: Assessment of strength, reflexes, and muscle bulk.
• Pulmonary Function Tests: Evaluation of respiratory muscle function.
• Family Screening: Cascade testing of at-risk family members.

Muscle Biopsy

When performed, muscle biopsy shows characteristic findings:

• Immunohistochemistry: Abnormal myopalladin accumulation or distribution.
• Electron Microscopy: Z-disc abnormalities and, in nemaline myopathy, rod-like structures.

Treatment and Management

Current Management

No disease-specific treatments exist, but standard therapies are used:

• Cardiac Management: Standard heart failure therapies, anticoagulation as indicated, and device therapy (pacemaker, ICD, or CRT) as needed.
• Respiratory Support: Non-invasive ventilation for respiratory insufficiency.
• Physical Therapy: Exercise and stretching to maintain function and prevent contractures.
• Surgical Intervention: Orthopedic procedures for severe contractures in some patients.

Experimental Therapies

Research is ongoing to develop novel treatments:

• Gene Therapy: Approaches to deliver functional MYPN or modify mutant allele expression.
• Small Molecule Therapies: Compounds that enhance protein folding or reduce aggregation.
• RNA-Based Therapies: Antisense oligonucleotides to modulate splicing or expression.

Research Directions

Biomarker Development

Current research focuses on identifying biomarkers for MYPN-related disease:

• Serum Biomarkers: Circulating myopalladin fragments or associated proteins.
• Imaging Markers: MRI-based quantification of cardiac and skeletal muscle involvement.
• Functional Measures: Quantitative strength testing and exercise capacity.

Genotype-Phenotype Correlations

Understanding how different mutations cause different phenotypes:

• Domain-Specific Effects: Mutations in different domains may cause distinct clinical presentations.
• Modifier Genes: Genetic modifiers may influence disease severity and progression.
• Environmental Factors: Lifestyle and environmental factors may modify disease expression.

Genetics

Inheritance Patterns

MYPN-related diseases show autosomal dominant inheritance:

• De Novo Mutations: Many cases result from spontaneous mutations with no family history.
• Variable Penetrance: Not all mutation carriers develop clinically apparent disease.
• Anticipation: Not typically observed in MYPN-related disease.

Known Variants

Over 40 pathogenic variants in MYPN have been identified:

• Missense Mutations: Most common, often affecting conserved residues in functional domains.
• Nonsense Mutations: Cause premature termination and truncated proteins.
• Splice Site Mutations: Lead to exon skipping or intron retention.
• Small Deletions/Insertions: Frameshift mutations that alter the protein sequence.

Prognosis

The prognosis for patients with MYPN-related disease varies significantly:

• Cardiac Disease: The leading cause of morbidity and mortality in MYPN mutation carriers.
• Skeletal Myopathy: Variable severity, with many patients maintaining ambulation.
• Age of Onset: Earlier onset is generally associated with more severe disease.
• Treatment Response: Most patients respond well to standard heart failure therapies.

References

See Also

• [Cardiomyopathy](/diseases/cardiomyopathy)](/diseases/cardiomyopathy)
• [Dilated Cardiomyopathy](/diseases/dilated-cardiomyopathy)](/diseases/cardiomyopathy)
• [Hypertrophic Cardiomyopathy](/diseases/hypertrophic-cardiomyopathy)](/diseases/cardiomyopathy)
• [Nemaline Myopathy](/diseases/nemaline-myopathy)
• [Myofibrillar Myopathy](/diseases/myofibrillar-myopathy)
• [Alpha-Actinin](/proteins/alpha-actinin)](/proteins)
• [Nebulin](/proteins/nebulin-protein)](/proteins)
• [Z-Disc](/entities/z-disc)](/entities)
• [Sarcomere](/entities/sarcomere)

External Links

• [NCBI Gene: MYPN](https://www.ncbi.nlm.nih.gov/gene/84665)
• [OMIM: 608002](https://www.omim.org/entry/608002)
• [UniProt: Q8WWI5](https://www.uniprot.org/uniprot/Q8WWI5)
• [Ensembl: ENSG00000138379](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138379)
• [HGNC: MYPN](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16438)